Biogen (BIIB) Reports New Data Showing Three Years of Continuous Treatment with Dual-Acting LEQEMBI Continues to Significantly Benefit Early Alzheimer's Disease Patients

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. IBM
3. PRIM
4. MU
5. DPZ
6. NAVN
7. DFTX
8. META
9. IMNN
10. ACN

Go back to Biogen (BIIB) Reports New Data Showing Three Years of Continuous Treatment with Dual-Acting LEQEMBI Continues to Significantly Benefit Early Alzheimer's Disease Patients

New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer's Disease Patients Presented at The Al

July 30, 2024 5:00 PM EDT

- 51% of No Tau / Low Tau Patients Showed Improved Cognition and Function Over Three Years; Only Lecanemab Has Clinical Data in No Tau / Low Tau Patient Group

- Clinical Data and Biomarkers Show Alzheimer's Disease Does Not Stop Progressing After Plaque Clearance. Lecanemab's Dual Action Supports Neuronal Function by Clearing Highly Toxic Protofibrils that Continue to Cause Neuronal Injury and Death After Rapid Plaque Clearance

- Lecanemab Slows Tau Spread Across All Brain Regions... More